Menu Search
Equities

Vertex Pharmaceuticals Inc

VX1:STU

Vertex Pharmaceuticals Inc

Actions
  • Price (EUR)433.85
  • Today's Change4.65 / 1.08%
  • Shares traded6.00
  • 1 Year change+34.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Vertex Pharmaceuticals Inc grew net income 8.96% from 3.32bn to 3.62bn primarily through revenue growth (8.93bn to 9.87bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 10.51% growth in revenues contributed enough to still see net income improve.
Gross margin86.12%
Net profit margin-4.52%
Operating margin-2.54%
Return on assets-2.18%
Return on equity-2.99%
Return on investment-2.64%
More ▼

Cash flow in USDView more

In 2023, Vertex Pharmaceuticals Inc did not generate a significant amount of cash. However, the company earned 3.54bn from its operations for a Cash Flow Margin of 35.84%. In addition the company used 3.14bn on investing activities and also paid 562.20m in financing cash flows.
Cash flow per share-0.9994
Price/Cash flow per share--
Book value per share60.65
Tangible book value per share53.20
More ▼

Balance sheet in USDView more

Vertex Pharmaceuticals Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio2.47
Quick ratio2.20
Total debt/total equity0.0073
Total debt/total capital0.0072
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)46.35
EPS (TTM) vs
TTM 1 year ago		-114.95
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.